Vepdegestrant Outperforms Fulvestrant in Advanced ER+HER2− Breast Cancer - Erika Hamilton
@erikahamilton9.bsky.social
oncodaily.com/insight/erik...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Vepdegestrant #Fulvestrant #BreastCancer
@erikahamilton9.bsky.social
oncodaily.com/insight/erik...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Vepdegestrant #Fulvestrant #BreastCancer
Erika Hamilton: Vepdegestrant Outperforms Fulvestrant in Advanced ER+HER2− Breast Cancer - OncoDaily
Erika Hamilton: Vepdegestrant Outperforms Fulvestrant in Advanced ER+HER2− Breast Cancer / Breast Cancer, cancer, Erika Hamilton, OncoDaily, Oncology
oncodaily.com
August 21, 2025 at 12:34 AM
Vepdegestrant Outperforms Fulvestrant in Advanced ER+HER2− Breast Cancer - Erika Hamilton
@erikahamilton9.bsky.social
oncodaily.com/insight/erik...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Vepdegestrant #Fulvestrant #BreastCancer
@erikahamilton9.bsky.social
oncodaily.com/insight/erik...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Vepdegestrant #Fulvestrant #BreastCancer
Final OS analysis from #FALCON:
✅ No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ #ABC
✅ 15% ⬇️ risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months)
@oncoalert.bsky.social
ascopubs.org/doi/full/10.12…
✅ No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ #ABC
✅ 15% ⬇️ risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months)
@oncoalert.bsky.social
ascopubs.org/doi/full/10.12…
January 19, 2025 at 1:24 PM
Final OS analysis from #FALCON:
✅ No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ #ABC
✅ 15% ⬇️ risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months)
@oncoalert.bsky.social
ascopubs.org/doi/full/10.12…
✅ No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ #ABC
✅ 15% ⬇️ risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months)
@oncoalert.bsky.social
ascopubs.org/doi/full/10.12…
Now online in JCO #postMonarch
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial
PURPOSECyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET)
are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal
growth factor re...
ascopubs.org
December 22, 2024 at 10:31 PM
Now online in JCO #postMonarch
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor.
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
December 11, 2024 at 9:42 PM
RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor.
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
INAVO120 trial: In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo. nej.md/3Zje7Vt
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
May 31, 2025 at 12:04 PM
INAVO120 trial: In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo. nej.md/3Zje7Vt
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
INAVO120 phase 3 trial: In PIK3CA-mutated advanced breast cancer, adding inavolisib to therapy with palbociclib and fulvestrant was previously shown to improve progression-free survival. Research findings on overall survival are summarized in a short video. nej.md/44TesRZ
#MedSky #Oncology
#MedSky #Oncology
July 12, 2025 at 7:02 PM
INAVO120 phase 3 trial: In PIK3CA-mutated advanced breast cancer, adding inavolisib to therapy with palbociclib and fulvestrant was previously shown to improve progression-free survival. Research findings on overall survival are summarized in a short video. nej.md/44TesRZ
#MedSky #Oncology
#MedSky #Oncology
Just presented at #ASCO25: VERITAC-2 results show vepdegestrant PROTAC more than doubles PFS vs fulvestrant in pts w/ ESR1-mutated, ER+/HER2– advanced #BreastCancer: brnw.ch/21wT43Z
#ASCODailyNews #bcsm
#ASCODailyNews #bcsm
May 31, 2025 at 6:58 PM
Just presented at #ASCO25: VERITAC-2 results show vepdegestrant PROTAC more than doubles PFS vs fulvestrant in pts w/ ESR1-mutated, ER+/HER2– advanced #BreastCancer: brnw.ch/21wT43Z
#ASCODailyNews #bcsm
#ASCODailyNews #bcsm
‘Breakthrough’ breast cancer therapy can slow advance of disease and prolong survival
‘Breakthrough’ breast cancer therapy can slow advance of disease and prolong survival
Study shows combination treatment for aggressive breast cancer delays advance by average 17 months and chemotherapy by two years
A new triple therapy for aggressive, advanced breast cancer slows the progression of the disease, delays the need for further chemotherapy and helps patients live longer, research reveals.
The combination treatment is made up of two targeted drugs: inavolisib and palbociclib, and the hormone therapy fulvestrant. It improved overall survival by an average of seven months, compared with the patients in the control group, who were given palbociclib and fulvestrant. Continue reading...
www.theguardian.com
May 31, 2025 at 12:13 PM
‘Breakthrough’ breast cancer therapy can slow advance of disease and prolong survival
NEWS: NICE has recommended capivasertib for advanced #BreastCancer.
The decision makes the targeted drug available, in combination with fulvestrant, for some NHS patients with the most common type of breast cancer.
Read more about the history of the drug⬇️
www.icr.ac.uk/about-us/icr...
The decision makes the targeted drug available, in combination with fulvestrant, for some NHS patients with the most common type of breast cancer.
Read more about the history of the drug⬇️
www.icr.ac.uk/about-us/icr...
April 11, 2025 at 6:37 AM
NEWS: NICE has recommended capivasertib for advanced #BreastCancer.
The decision makes the targeted drug available, in combination with fulvestrant, for some NHS patients with the most common type of breast cancer.
Read more about the history of the drug⬇️
www.icr.ac.uk/about-us/icr...
The decision makes the targeted drug available, in combination with fulvestrant, for some NHS patients with the most common type of breast cancer.
Read more about the history of the drug⬇️
www.icr.ac.uk/about-us/icr...
In advanced breast cancer, progression-free survival was significantly longer with vepdegestrant than with fulvestrant among patients with ESR1 mutations but not in the full patient population. Full VERITAC-2 phase 3 trial results: nej.md/3ZoCL7g
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
May 31, 2025 at 12:09 PM
In advanced breast cancer, progression-free survival was significantly longer with vepdegestrant than with fulvestrant among patients with ESR1 mutations but not in the full patient population. Full VERITAC-2 phase 3 trial results: nej.md/3ZoCL7g
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
16/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
🔙 to our case
EMBER3 would be a great option, but based on availability, pt got elacestrant
🚫 abema+fulvestrant:
-ESR1 Y537S 👉fulvestrant resistance.
-POSTMONARCH👉modest PFS benof abema+fulv vs placebo+fulv AND 🚫benefit in subgroup w/ prior ribo
🔙 to our case
EMBER3 would be a great option, but based on availability, pt got elacestrant
🚫 abema+fulvestrant:
-ESR1 Y537S 👉fulvestrant resistance.
-POSTMONARCH👉modest PFS benof abema+fulv vs placebo+fulv AND 🚫benefit in subgroup w/ prior ribo
January 15, 2025 at 1:45 AM
16/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
🔙 to our case
EMBER3 would be a great option, but based on availability, pt got elacestrant
🚫 abema+fulvestrant:
-ESR1 Y537S 👉fulvestrant resistance.
-POSTMONARCH👉modest PFS benof abema+fulv vs placebo+fulv AND 🚫benefit in subgroup w/ prior ribo
🔙 to our case
EMBER3 would be a great option, but based on availability, pt got elacestrant
🚫 abema+fulvestrant:
-ESR1 Y537S 👉fulvestrant resistance.
-POSTMONARCH👉modest PFS benof abema+fulv vs placebo+fulv AND 🚫benefit in subgroup w/ prior ribo
2/20 #TumorBoardTuesday
Poll: What would you do next?
1. Sequence biopsied site of metastatic recurrence +/- ctDNA
2. Start ribociclib, switch endocrine therapy to fulvestrant
3. Start inavolisib, palbociclib and fulvestrant
4. Options 1 and 3 concurrently
@dr-rshatsky.bsky.social
Poll: What would you do next?
1. Sequence biopsied site of metastatic recurrence +/- ctDNA
2. Start ribociclib, switch endocrine therapy to fulvestrant
3. Start inavolisib, palbociclib and fulvestrant
4. Options 1 and 3 concurrently
@dr-rshatsky.bsky.social
January 15, 2025 at 1:02 AM
2/20 #TumorBoardTuesday
Poll: What would you do next?
1. Sequence biopsied site of metastatic recurrence +/- ctDNA
2. Start ribociclib, switch endocrine therapy to fulvestrant
3. Start inavolisib, palbociclib and fulvestrant
4. Options 1 and 3 concurrently
@dr-rshatsky.bsky.social
Poll: What would you do next?
1. Sequence biopsied site of metastatic recurrence +/- ctDNA
2. Start ribociclib, switch endocrine therapy to fulvestrant
3. Start inavolisib, palbociclib and fulvestrant
4. Options 1 and 3 concurrently
@dr-rshatsky.bsky.social
Inavolisib was recently approved in combination w/ palbo and fulvestrant for MBC w/ PIK3CA mutation - side effects are still 😳 #SABCS24
December 10, 2024 at 8:00 PM
Inavolisib was recently approved in combination w/ palbo and fulvestrant for MBC w/ PIK3CA mutation - side effects are still 😳 #SABCS24
This treatment is a cakewalk compared to my monthly injections of fulvestrant!! Took a quick nap a while ago! All good!! 💙👍
March 13, 2026 at 11:20 PM
This treatment is a cakewalk compared to my monthly injections of fulvestrant!! Took a quick nap a while ago! All good!! 💙👍
What about endocrine resistance and ESR1 mutations? all ESR1 mutations are not the same - mutations matter, especially in terms of whether fulvestrant will be effective. #SABCS24
December 11, 2024 at 2:10 PM
What about endocrine resistance and ESR1 mutations? all ESR1 mutations are not the same - mutations matter, especially in terms of whether fulvestrant will be effective. #SABCS24
Research led by @danafarbernews.bsky.social’s Dr. Adrienne Waks shows combination therapy of avutometinib, abemaciclib and fulvestrant is active, safe in CDK4/6 inhibitor–resistant HR+/HER2– metastatic breast cancer, reports @onclive.bsky.social from #AACR25. bit.ly/3YTUmni
Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer
Avutometinib plus abemaciclib and fulvestrant had manageable toxicity in CDK4/6-resistant, HR+/HER2– metastatic breast cancer.
bit.ly
April 30, 2025 at 5:30 PM
Research led by @danafarbernews.bsky.social’s Dr. Adrienne Waks shows combination therapy of avutometinib, abemaciclib and fulvestrant is active, safe in CDK4/6 inhibitor–resistant HR+/HER2– metastatic breast cancer, reports @onclive.bsky.social from #AACR25. bit.ly/3YTUmni
#Medsky🧪 #pharmasky #oncosky #inavolisib + #palbociclib–fulvestrant with significant overall survival benefit, vs placebo+ pfulvestrant. Hyperglycemia, stomatitis or mucosal inflammation, gastrointestinal toxic effects, ocular side effects were reported more frequently with #inavolisib vs placebo.
In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo. Full INAVO120 trial results and Research Summary: nej.md/3Zje7Vt
#MedSky #Oncology
#MedSky #Oncology
July 15, 2025 at 7:12 PM
#Medsky🧪 #pharmasky #oncosky #inavolisib + #palbociclib–fulvestrant with significant overall survival benefit, vs placebo+ pfulvestrant. Hyperglycemia, stomatitis or mucosal inflammation, gastrointestinal toxic effects, ocular side effects were reported more frequently with #inavolisib vs placebo.
Now online in Cancer Discovery: ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-mutant Breast Cancer - by Belinda Kingston, Nicholas Turner, and colleagues doi.org/10.1158/2159...
November 20, 2023 at 7:52 PM
Now online in Cancer Discovery: ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-mutant Breast Cancer - by Belinda Kingston, Nicholas Turner, and colleagues doi.org/10.1158/2159...
In the INAVO120 trial, inavolisib+palbociclib-fulvestrant improved PFS in PIK3CA-mutated, HR+HER2- advanced breast cancer vs placebo+palbociclib-fulvestrant. PMID:40454641, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2501796 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1056/NEJMoa2501796
No description available
doi.org
November 3, 2025 at 1:10 AM
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with HR+, HER2+ metastatic #BreastCancer
www.thelancet.com/journals/lan...
Results support further investigation of this chemotherapy-free triplet approach as a potential tx option
@erikahamilton9.bsky.social
www.thelancet.com/journals/lan...
Results support further investigation of this chemotherapy-free triplet approach as a potential tx option
@erikahamilton9.bsky.social
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single...
Zanidatamab plus palbociclib and fulvestrant was generally safe and showed promising
antitumour activity, supporting further evaluation of this chemotherapy-free triplet
regimen.
www.thelancet.com
May 21, 2025 at 8:26 AM
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with HR+, HER2+ metastatic #BreastCancer
www.thelancet.com/journals/lan...
Results support further investigation of this chemotherapy-free triplet approach as a potential tx option
@erikahamilton9.bsky.social
www.thelancet.com/journals/lan...
Results support further investigation of this chemotherapy-free triplet approach as a potential tx option
@erikahamilton9.bsky.social
17/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
January 15, 2025 at 1:46 AM
17/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
The @US_FDA approved the targeted therapy gedatolisib with fulvestrant—with or without palbociclib—for certain HR-positive, HER2-negative advanced breast cancers that do not have a PIK3CA mutation after progressing on or after prior endocrine therapy: buff.ly/YXouLea
FDA approves gedatolisib with fulvestrant, with or without palbociclib
On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor…
www.fda.gov
July 14, 2026 at 8:27 PM
The @US_FDA approved the targeted therapy gedatolisib with fulvestrant—with or without palbociclib—for certain HR-positive, HER2-negative advanced breast cancers that do not have a PIK3CA mutation after progressing on or after prior endocrine therapy: buff.ly/YXouLea
10/20 #TumorBoardTuesday
What would you select as next line of therapy?
1. Abemaciclib+fulvestrant
2. Elacestrant
3. Evaluate for clinical trials involving novel SERDs
@dr-rshatsky.bsky.social
What would you select as next line of therapy?
1. Abemaciclib+fulvestrant
2. Elacestrant
3. Evaluate for clinical trials involving novel SERDs
@dr-rshatsky.bsky.social
January 15, 2025 at 1:28 AM
10/20 #TumorBoardTuesday
What would you select as next line of therapy?
1. Abemaciclib+fulvestrant
2. Elacestrant
3. Evaluate for clinical trials involving novel SERDs
@dr-rshatsky.bsky.social
What would you select as next line of therapy?
1. Abemaciclib+fulvestrant
2. Elacestrant
3. Evaluate for clinical trials involving novel SERDs
@dr-rshatsky.bsky.social
4/20 #TumorBoardTuesday
👩⚕️Mini Tutorial 1👩⚕️
Oct 2024, FDA approved inavolisib, palbociclib, and fulvestrant in endocrine resistant HR+/HER2- advanced breast cancer, based on the phase 3, INAVO120 study
@dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 1👩⚕️
Oct 2024, FDA approved inavolisib, palbociclib, and fulvestrant in endocrine resistant HR+/HER2- advanced breast cancer, based on the phase 3, INAVO120 study
@dr-rshatsky.bsky.social
January 15, 2025 at 1:15 AM
4/20 #TumorBoardTuesday
👩⚕️Mini Tutorial 1👩⚕️
Oct 2024, FDA approved inavolisib, palbociclib, and fulvestrant in endocrine resistant HR+/HER2- advanced breast cancer, based on the phase 3, INAVO120 study
@dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 1👩⚕️
Oct 2024, FDA approved inavolisib, palbociclib, and fulvestrant in endocrine resistant HR+/HER2- advanced breast cancer, based on the phase 3, INAVO120 study
@dr-rshatsky.bsky.social
Great news!
The SMC has recommended both elascestrant, and capivasertib with fulvestrant for use on the NHS in Scotland for eligible metastatic breast cancer patients: breastcancernow.org/about-us/med...
The SMC has recommended both elascestrant, and capivasertib with fulvestrant for use on the NHS in Scotland for eligible metastatic breast cancer patients: breastcancernow.org/about-us/med...
We respond to SMC decision recommending elacestrant & capivasertib with fulvestrant
Melanie Sturtevant, associate director of policy, evidence and influencing at Breast Cancer Now, said:
breastcancernow.org
September 8, 2026 at 8:39 AM
Great news!
The SMC has recommended both elascestrant, and capivasertib with fulvestrant for use on the NHS in Scotland for eligible metastatic breast cancer patients: breastcancernow.org/about-us/med...
The SMC has recommended both elascestrant, and capivasertib with fulvestrant for use on the NHS in Scotland for eligible metastatic breast cancer patients: breastcancernow.org/about-us/med...